286 related articles for article (PubMed ID: 28060738)
1. The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal IG-VDJ sequences at diagnosis in patients with follicular lymphoma.
Sarkozy C; Huet S; Carlton VE; Fabiani B; Delmer A; Jardin F; Delfau-Larue MH; Hacini M; Ribrag V; Guidez S; Faham M; Salles G
Oncotarget; 2017 Jan; 8(5):8765-8774. PubMed ID: 28060738
[TBL] [Abstract][Full Text] [Related]
2. Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma.
Maron SB; Chase LM; Lomnicki S; Kochanny S; Moore KL; Joshi SS; Landron S; Johnson J; Kiedrowski LA; Nagy RJ; Lanman RB; Kim ST; Lee J; Catenacci DVT
Clin Cancer Res; 2019 Dec; 25(23):7098-7112. PubMed ID: 31427281
[TBL] [Abstract][Full Text] [Related]
3. VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma.
Jiang Y; Nie K; Redmond D; Melnick AM; Tam W; Elemento O
J Vis Exp; 2015 Dec; (106):e53215. PubMed ID: 26780364
[TBL] [Abstract][Full Text] [Related]
4. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
[TBL] [Abstract][Full Text] [Related]
5. Tissue-Matched IgH Gene Rearrangement of Circulating Tumor DNA Shows Significant Value in Predicting the Progression of Diffuse Large B Cell Lymphoma.
Zhao K; Zheng X; Liu X; Liu T; Ke Z; Zhu F; Wen Q; Xin B; Li Q; Zhang L
Oncologist; 2024 May; 29(5):e672-e680. PubMed ID: 38297976
[TBL] [Abstract][Full Text] [Related]
6. Very early response of circulating tumour-derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non-small cell lung cancer.
Iijima Y; Hirotsu Y; Amemiya K; Ooka Y; Mochizuki H; Oyama T; Nakagomi T; Uchida Y; Kobayashi Y; Tsutsui T; Kakizaki Y; Goto T; Miyashita Y; Omata M
Eur J Cancer; 2017 Nov; 86():349-357. PubMed ID: 29078173
[TBL] [Abstract][Full Text] [Related]
7. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.
Pastore A; Jurinovic V; Kridel R; Hoster E; Staiger AM; Szczepanowski M; Pott C; Kopp N; Murakami M; Horn H; Leich E; Moccia AA; Mottok A; Sunkavalli A; Van Hummelen P; Ducar M; Ennishi D; Shulha HP; Hother C; Connors JM; Sehn LH; Dreyling M; Neuberg D; Möller P; Feller AC; Hansmann ML; Stein H; Rosenwald A; Ott G; Klapper W; Unterhalt M; Hiddemann W; Gascoyne RD; Weinstock DM; Weigert O
Lancet Oncol; 2015 Sep; 16(9):1111-1122. PubMed ID: 26256760
[TBL] [Abstract][Full Text] [Related]
8. Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival.
Baumgartner JM; Raymond VM; Lanman RB; Tran L; Kelly KJ; Lowy AM; Kurzrock R
Ann Surg Oncol; 2018 Aug; 25(8):2400-2408. PubMed ID: 29948422
[TBL] [Abstract][Full Text] [Related]
9. Correlation of genomic alterations between tumor tissue and circulating tumor DNA by next-generation sequencing.
Chang YS; Fang HY; Hung YC; Ke TW; Chang CM; Liu TY; Chen YC; Chao DS; Huang HY; Chang JG
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2167-2175. PubMed ID: 30203147
[TBL] [Abstract][Full Text] [Related]
10. Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer.
Yang J; Gong Y; Lam VK; Shi Y; Guan Y; Zhang Y; Ji L; Chen Y; Zhao Y; Qian F; Chen J; Li P; Zhang F; Wang J; Zhang X; Yang L; Kopetz S; Futreal PA; Zhang J; Yi X; Xia X; Yu P
Cell Death Dis; 2020 May; 11(5):346. PubMed ID: 32393783
[TBL] [Abstract][Full Text] [Related]
11. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study.
Roschewski M; Dunleavy K; Pittaluga S; Moorhead M; Pepin F; Kong K; Shovlin M; Jaffe ES; Staudt LM; Lai C; Steinberg SM; Chen CC; Zheng J; Willis TD; Faham M; Wilson WH
Lancet Oncol; 2015 May; 16(5):541-9. PubMed ID: 25842160
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer.
Guan X; Liu B; Niu Y; Dong X; Zhu X; Li C; Li L; Yi Z; Sun X; Chen H; Lu S; Ma F
Breast; 2020 Feb; 49():261-266. PubMed ID: 31927339
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic and prognostic value of circulating tumor DNA in gastric cancer: a meta-analysis.
Gao Y; Zhang K; Xi H; Cai A; Wu X; Cui J; Li J; Qiao Z; Wei B; Chen L
Oncotarget; 2017 Jan; 8(4):6330-6340. PubMed ID: 28009985
[TBL] [Abstract][Full Text] [Related]
14. Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients.
Xerri L; Huet S; Venstrom JM; Szafer-Glusman E; Fabiani B; Canioni D; Chassagne-Clément C; Dartigues-Cuilléres P; Charlotte F; Laurent C; Gelas-Dore B; Bolen CR; Punnoose E; Bouabdallah R; Brice P; Morschhauser F; Cartron G; Olive D; Salles G;
Hum Pathol; 2017 Jun; 64():128-136. PubMed ID: 28414090
[TBL] [Abstract][Full Text] [Related]
15. Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients.
Ashida A; Sakaizawa K; Uhara H; Okuyama R
Acta Derm Venereol; 2017 Nov; 97(10):1212-1218. PubMed ID: 28681063
[TBL] [Abstract][Full Text] [Related]
16. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
[TBL] [Abstract][Full Text] [Related]
17. Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors.
Cao Y; Zhu T; Zhang P; Xiao M; Yi S; Yang Y; Li Q; Ling S; Wang Y; Gao L; Zhu L; Wang J; Wang N; Huang L; Zhang P; Zhai Q; Qiu L; Zhou J
Oncotarget; 2016 Dec; 7(50):83294-83307. PubMed ID: 27825110
[TBL] [Abstract][Full Text] [Related]
18. Serial profiling of circulating tumor DNA for optimization of anti-VEGF chemotherapy in metastatic colorectal cancer patients.
Yamauchi M; Urabe Y; Ono A; Miki D; Ochi H; Chayama K
Int J Cancer; 2018 Apr; 142(7):1418-1426. PubMed ID: 29134647
[TBL] [Abstract][Full Text] [Related]
19. Capturing Tumor Heterogeneity and Clonal Evolution by Circulating Tumor DNA Profiling.
Scherer F
Recent Results Cancer Res; 2020; 215():213-230. PubMed ID: 31605231
[TBL] [Abstract][Full Text] [Related]
20. Methods for Measuring ctDNA in Lymphomas.
Rossi D; Condoluci A; Spina V; Gaidano G
Methods Mol Biol; 2019; 1881():253-265. PubMed ID: 30350211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
